Updated on July 1, 2026

Cutting-Edge Protein Therapeutics and Targeted Protein Degradation

Overview

For decades, small-molecule drugs dominated pharmaceutical pipelines. They were predictable to manufacture, orally bioavailable, and well understood by regulators. But they carry a fundamental limitation: they can only bind to targets with accessible pockets — enzymes, receptors, ion channels. Estimates suggest this druggable portion accounts for no more than 10–15% of the human proteome. The remaining portion — long considered beyond the reach of conventional small molecules, and often referred to as the undruggable space — includes transcription factors, protein-protein interactions, and intracellular scaffolding proteins implicated in some of the most treatment-resistant cancers and diseases known to medicine.

Protein therapeutics — and more broadly, protein-targeting therapeutics — are dismantling that barrier. In this article, I use Protein therapeutics to describe biologic modalities that bind, redirect, or modulate proteins, alongside targeted protein degradation technologies that expand access to intracellular targets but are not themselves biologics.

The sections and therapeutic modalities covered in this article are listed below. Click any item to jump directly to that section.

• Antibody-Drug Conjugates (ADCs)
• Bispecific Antibodies
• PROTACs (targeted protein degradation small molecules)
• Engineered Cytokines
• Cell-Penetrating Peptides (CPPs)
• Modality Comparison at a Glance
• Cross-Cutting Development Challenges
• Strategic Implications for the Life Sciences Ecosystem
• Conclusion

The global biologics market — encompassing monoclonal antibodies, cell therapies, gene therapies, plasma-derived proteins, and vaccines — was valued at approximately $487 billion in 2025 and is projected to exceed $1.2 trillion by 2035. Within that broader landscape, protein therapeutics represent a major commercial segment, valued at approximately $300–400 billion in 2025 and forecast to continue growing a compound annual growth rate of (CAGR) ~6.5% through 2035. Because market reports use different definitions and inclusion criteria — some counting plasma-derived proteins and hormones, others focusing narrowly on recombinant biologics — these numbers should be interpreted as composite estimates rather than a single standardized market basket.

Monoclonal antibodies currently account for the largest share of this segment, underscoring the commercial maturity of first-generation protein modalities. The fastest growth — and the most significant unmet medical need — lies in the next-generation modalities that are now reshaping oncology, immunology, and beyond. Antibody-drug conjugates, valued at approximately $14–17 billion in 2025, are projected to reach roughly $33–45 billion by 2035 based on a composite of independent market forecasts. Bispecific antibodies, currently valued at approximately $9–15 billion depending on the scope of formats and geographic markets include, are forecast to grow substantially over the same period. And while targeted protein degradation technologies — including PROTACs and molecular glues — represent a nascent commercial market today, they are gaining clinical momentum and attracting substantial R&D investment and partnership activity from major pharmaceutical and biotechnology organizations. It is these five modalities — their science, their development challenges, and their strategic implications — that are the focus of this article.

1. Antibody-Drug Conjugates (ADCs): Precision Payload Delivery

Mechanism & Therapeutic Rationale

ADCs are engineered constructs linking a monoclonal antibody to a cytotoxic small-molecule payload via a chemical linker. The antibody functions as a guided delivery vehicle, binding to a tumor-associated antigen on the surface of cancer cells. Upon internalization, the linker is cleaved and the payload is released intracellularly — killing the target cell while, in theory, sparing healthy tissue. This “magic bullet” concept, first envisioned by Paul Ehrlich over a century ago, has reached clinical maturity in the last decade.

FDA-Approved Examples & Pipeline Depth

As of 2026, the FDA has approved more than 15 ADCs, including landmark therapies such as trastuzumab deruxtecan (Enhertu) for HER2-positive, HER2-low and HER2-ultralow breast cancers, gastric, and lung cancers; mirvetuximab soravtansine (Elahere) for folate receptor-alpha positive ovarian cancer; ado-trastuzumab emtansine (Kadcyla) for HER2-positive breast cancer; brentuximab vedotin (Adcetris) for CD30-expressing lymphomas; sacituzumab govitecan (Trodelvy) for triple-negative breast cancer, HR+/HER2- breast cancer and urothelial cancer; and enfortumab vedotin (Padcev) for urothelial carcinoma. A defining trend across next-generation ADCs is the dominance of topoisomerase I inhibitor payloads — most notably the DXd payload used in Enhertu — which have shown broader therapeutic windows and bystander killing effects compared to earlier tubulin-targeting agents. With over 100 ADCs currently in clinical development, this is now one of the most competitive and commercially significant spaces in oncology drug development.

Key Therapeutic Applications

ADCs have found their strongest clinical footing in oncology, particularly solid tumors and hematologic malignancies where target antigen expression is high and relatively tumor-selective. Emerging programs are expanding into infectious diseases and autoimmune indications, though oncology remains the dominant clinical territory.

Development Challenges

• Linker-Payload Chemistry: The linker must be stable in systemic circulation but efficiently cleaved inside target cells. Premature payload release drives off-target toxicity; insufficient release reduces efficacy. Optimizing this balance requires sophisticated conjugation chemistry and robust analytical characterization.
• Drug-to-Antibody Ratio (DAR) Control: DAR — the average number of drug molecules per antibody — must be tightly controlled. High DAR can compromise antibody pharmacokinetics and cause aggregation; low DAR undermines potency. DAR heterogeneity is one of the most analytically demanding aspects of ADC development.
• Highly Potent Active Pharmaceutical Ingredient (HPAPI) Handling: ADC payloads are typically cytotoxic at nanomolar concentrations. Manufacturing requires specialized containment infrastructure, limiting the pool of organizations capable of producing them at scale.
• Therapeutic Window: Balancing the minimum effective dose against the maximum tolerated dose remains a central clinical development challenge, particularly as next-generation ADCs push into novel antigen targets with lower tumor selectivity.

2. Bispecific Antibodies: Redirecting Immune Cells to Tumors

Mechanism & Therapeutic Rationale

Bispecific antibodies (bsAbs) are engineered proteins capable of simultaneously binding two distinct antigens or epitopes. The most clinically impactful design co-engages a tumor-associated antigen on cancer cells and an activating receptor on immune effector cells — most commonly CD3 on T-cells — physically bridging the two and triggering tumor cell killing independent of MHC-peptide presentation. This mechanism bypasses one of the most common resistance mechanisms to conventional immunotherapy.

FDA-Approved Examples & Pipeline Depth

The FDA has approved a rapidly expanding portfolio of bispecific antibodies. Blinatumomab (Blincyto), targeting CD19×CD3, demonstrated durable remissions in relapsed/refractory B-cell acute lymphoblastic leukemia. More recently, teclistamab (Tecvayli) and elranatamab (Elrexfio) have received approvals in multiple myeloma, targeting BCMA×CD3. Mosunetuzumab (Lunsumio) and glofitamab (Columvi), both targeting CD20×CD3, have expanded the portfolio into follicular lymphoma and diffuse large B-cell lymphoma respectively. As of 2026, ~15 bispecific antibodies have received FDA approval, and over 50 additional candidates are in Phase II/III clinical development across hematologic malignancies, solid tumors, and autoimmune diseases.

Key Therapeutic Applications

Bispecifics have demonstrated particular utility in hematologic cancers, where the tumor microenvironment is more accessible to T-cell engagement. Solid tumor programs represent the next frontier, though tumor microenvironment immunosuppression and target antigen heterogeneity remain significant hurdles. Beyond oncology, bispecifics targeting dual inflammatory mediators are showing promise in autoimmune indications.

Development Challenges

• Chain Mispairing: Producing bispecific antibodies with correct heavy- and light-chain pairing remains a significant manufacturing challenge. Unwanted homodimer or mismatched chain formation during expression can dramatically reduce yield and require elaborate purification strategies. Platform solutions such as knob-into-hole engineering, CrossMab, and common light-chain formats partially address this but add formulation complexity.
• Platform IP Landscape: The bispecific antibody field is heavily patented. Navigating freedom-to-operate — particularly around bispecific format patents, Fc engineering approaches, and CD3-engaging domains— adds legal and strategic complexity for emerging organizations.
• Cytokine Release Syndrome (CRS): T-cell engagers carry an inherent risk of triggering systemic cytokine release, particularly at first dose. Managing CRS through step-up dosing protocols and prophylactic interventions is a standard but costly component of clinical trial design.
• Solid Tumor Penetration: Unlike hematologic tumors, solid tumors present physical and immunological barriers to bispecific efficacy. Poor tumor infiltration and T-cell exhaustion within the immunosuppressive tumor microenvironment remain active areas of research.

3. PROTACs: Targeted Protein Degradation

Mechanism & Therapeutic Rationale

Proteolysis-Targeting Chimeras (PROTACs) represent a conceptual departure from conventional drug design. Rather than occupying and blocking a disease protein’s active site, PROTACs recruit the cell’s own ubiquitin-proteasome degradation machinery to eliminate the target protein entirely. A PROTAC molecule consists of two binding domains connected by a chemical linker: one domain binds the target protein, the other recruits an E3 ubiquitin ligase. The resulting ternary complex tags the target for proteasomal degradation — and because the PROTAC is catalytic rather than stoichiometric, a single molecule can repeatedly drive multiple rounds of target degradation.

This mechanism is particularly powerful for transcription factors, scaffolding proteins, and mutant oncoproteins that lack classical inhibitor binding sites — targets that have historically been considered intractable to conventional small molecules.

Pipeline Activity & Regulatory Milestones

PROTACs are the newest modality among those discussed here and have not yet achieved FDA approval as of the time of writing, though the field has seen significant clinical momentum.

ARV-110 (bavdegalutamide), targeting the androgen receptor in metastatic castration-resistant prostate cancer, has advanced through Phase I/II development, with activity observed in molecularly selected patient populations, including tumors harboring AR T878X/H875Y alterations. ARV-471 (vepdegestrant), targeting the estrogen receptor in ER-positive/HER2-negative advanced breast cancer, reached a major regulatory milestone in the PROTAC field after positive Phase 3 VERITAC-2 results; Arvinas and Pfizer submitted an NDA to the FDA in 2025, positioning vepdegestrant as the first PROTAC degrader to reach late-stage regulatory review.

Key Therapeutic Applications

Oncology remains the primary clinical application, with programs targeting androgen receptor, estrogen receptor, BRD4, BCL-XL, and KRAS variants — proteins historically considered intractable. Early work in neurodegeneration (tau protein targeting in Alzheimer’s disease) and antiviral applications is broadening the therapeutic landscape considerably.

Development Challenges

• CMC and Molecular Size: PROTACs occupy an unusual space between small molecules and biologics — typically molecular weights of 700–1,100 Da — placing them beyond Lipinski’s Rule of Five. This creates real challenges for oral bioavailability, membrane permeability, and formulation, and requires novel delivery strategies to achieve adequate intracellular exposure.
• Ternary Complex Optimization: Efficacy depends not just on binding affinity to the target and the E3 ligase independently, but on the geometry and cooperativity of the three-molecule ternary complex. Rational design of linker length and chemistry to promote productive ternary complex formation remains highly empirical.
• E3 Ligase Dependency: The field relies heavily on a small number of well-characterized E3 ligases (CRBN, VHL). This creates potential resistance mechanisms via E3 ligase downregulation in treated tumors — an emerging clinical concern as the first long-term efficacy data matures.
• Regulatory Novelty: As a first-in-class small-molecule degradation mechanism, PROTACs face evolving regulatory expectations. FDA is treating them largely within established small-molecule IND/NDA frameworks, but novel analytical methods for characterizing ternary complex formation, degradation kinetics, and selectivity profiling are still being standardized across the industry.

4. Engineered Cytokines: Precision Immunomodulation

Mechanism & Therapeutic Rationale
Cytokines are signaling proteins that regulate immune cell activation, proliferation, and function. As natural orchestrators of immune response, they hold obvious therapeutic appeal — but native cytokines like IL-2 and interferon-alpha are notoriously toxic at therapeutic doses, producing severe systemic immune activation that limits clinical utility. Engineered cytokines — including cytokine fusion proteins, orthogonal cytokines, and conditionally active variants — seek to preserve the immunostimulatory potency of native cytokines while restricting activity to the tumor microenvironment or specific immune compartments.

Pipeline Activity & Lessons from First-Generation Programs
First-generation IL-2 engineering programs demonstrated both the promise and the limitations of cytokine biasing. High-profile Phase III setbacks in melanoma combination studies exposed the persistent difficulty of separating therapeutic efficacy from systemic toxicity at clinically relevant doses, and underscored the need for more spatially and conditionally controlled cytokine activity. The field has incorporated those lessons. Multiple next-generation programs incorporating IL-10, IL-12, IL-15, and interferon engineering are being explored in early-phase development, with the design emphasis now firmly on tumor-targeted or conditionally activated formats that restrict immune stimulation to the relevant tissue compartment.frontiersin+4

Key Therapeutic Applications
Engineered cytokines are positioned primarily in immuno-oncology, where the goal is to reinvigorate exhausted or excluded T cells and NK cells within the tumor microenvironment. Autoimmune applications are also emerging, particularly for immunosuppressive cytokine engineering aimed at dampening — rather than amplifying — immune activity in conditions like lupus and inflammatory bowel disease.academic.oup+1

Development Challenges

• On-Target Toxicity: The fundamental challenge with cytokine engineering remains systemic toxicity. Even well-engineered variants can produce clinically limiting adverse effects when exposure is not sufficiently localized.frontiersin+1
• Pharmacokinetic Management: Native cytokines have extremely short half-lives. Fusion proteins, PEGylation, and Fc-coupling strategies extend exposure but introduce new analytical and immunogenicity considerations.frontiersin+1
• Combination Complexity: Engineered cytokines are often most compelling as combination partners with checkpoint inhibitors or cellular therapies, but combination trial design substantially increases development complexity and cost.academic.oup+1
• Manufacturing Scale: Cytokine-based formats can present expression, folding, purification, stability, and batch-consistency challenges, especially when post-translational modifications are required.

5. Cell-Penetrating Peptides (CPPs): Unlocking the Intracellular Space

Mechanism & Therapeutic Rationale

The plasma membrane represents one of biology’s most effective barriers to drug delivery. Most large biologics — antibodies, cytokines, recombinant proteins — are restricted to extracellular targets. Cell-penetrating peptides (CPPs) are short amino acid sequences, typically 5–30 residues in length, capable of translocating across the plasma membrane and carrying therapeutic cargo into the intracellular space. The precise mechanism of cellular uptake remains an active area of scientific debate: some CPPs appear to enter through direct membrane translocation, while others are taken up primarily via endocytosis — a distinction with important implications for intracellular trafficking and cargo delivery efficiency. Cargoes can include nucleic acids, proteins, imaging agents, and small-molecule drugs, opening access to intracellular targets that are structurally inaccessible to conventional biologics.

Research Programs & Applications

CPPs remain primarily in preclinical and early clinical development. Research programs include CPP-conjugated antisense or exon-skipping oligonucleotide programs for Duchenne muscular dystrophy, intracellular delivery of p53-activating peptides in oncology, and CPP-enabled delivery of CRISPR machinery. Their versatility as delivery platforms — rather than standalone therapeutics — represents their most commercially tractable near-term application. It is also worth noting that lipid nanoparticles (LNPs) represent an increasingly relevant adjacent technology, providing a competing and in some contexts complementary approach to intracellular cargo delivery, particularly for nucleic acid therapeutics.

Key Therapeutic Applications

The most promising near-term therapeutic areas include neuromuscular diseases — where intracellular nucleic acid delivery is mechanistically essential — oncology, and as a delivery enabler for gene-editing tools that require nuclear access.

Development Challenges

• Selectivity and Off-Target Uptake: Most CPPs lack intrinsic cell-type selectivity, distributing broadly across tissues upon systemic administration. Achieving tumor- or tissue-specific delivery requires additional targeting moieties, adding molecular complexity.
• Endosomal Escape: Regardless of the initial entry mechanism, a significant fraction of CPP-cargo conjugates that enter cells become trapped in endosomes and are degraded before reaching their intracellular targets. Endosomal escape efficiency is one of the field’s most critical unresolved challenges, and improving it without sacrificing selectivity remains a central design challenge.
• Immunogenicity and Stability: Peptide-based therapeutics are susceptible to proteolytic degradation in serum and may elicit immune responses upon repeated dosing. Stability engineering approaches — including D-amino acid substitution, cyclization, and peptide stapling — can improve this but add synthetic complexity.
• Regulatory and Analytical Immaturity: Unlike ADCs or bispecific antibodies, CPP-conjugate therapeutics lack established regulatory precedents for characterization, potency assays, and release testing, requiring sponsors to engage early with regulators to define acceptable analytical frameworks.

6. Modality Comparison at a Glance

7. Cross-Cutting Development Challenges

Beyond the modality-specific hurdles outlined above, several challenges apply broadly across next-generation therapeutic modalities and deserve attention from both development and commercial strategy perspectives.

Immunogenicity is a universal concern for most exogenous biologics and protein-based therapeutics. Anti-drug antibody (ADA) formation can neutralize therapeutic activity, alter pharmacokinetics, and in rare cases cause serious adverse events. Immunogenicity risk must be assessed early through in silico T-cell epitope prediction, in vitro assays, and clinical ADA monitoring — a requirement that is especially relevant for the protein-based modalities discussed here.

Analytical characterization complexity is substantially greater for these modalities than for conventional monoclonal antibodies. ADCs require DAR distribution analysis; bispecifics require dual-binding confirmation and mispairing detection; PROTACs require target-degradation and ternary complex characterization; and CPP-conjugates require intracellular trafficking studies. Novel analytical methods often need to be developed de novo and qualified for regulatory submission, adding both time and cost to development timelines.

Regulatory pathways and expedited designations. ADCs and bispecific antibodies have often leveraged FDA’s Breakthrough Therapy and Accelerated Approval pathways, enabling faster access to patients with unmet medical needs while post-approval confirmatory data mature. For newer modalities such as PROTACs and CPPs, sponsors should engage early with regulators on study design, endpoints, CMC expectations, and the applicability of these pathways — as the precedents being established now will shape the regulatory landscape for years to come.

Combination strategies. Nearly all five modalities are showing their greatest clinical promise in combination with checkpoint inhibitors, targeted therapies, or cellular therapies. Combination development introduces significant protocol complexity, cost-sharing challenges between sponsors, and regulatory questions around contribution of effect — all of which require thoughtful early planning.

Cost of goods and access. As these modalities advance toward approval, manufacturing cost complexity translates directly into pricing and reimbursement challenges. Payers and health technology assessment bodies are scrutinizing the cost-effectiveness of advanced therapeutic modalities with unprecedented rigor. For organizations developing these therapies, building a credible cost-of-goods narrative alongside clinical development is no longer optional — it is a commercial imperative.

8. Strategic Implications for the Life Sciences Ecosystem

For Biopharmaceutical Companies
Large pharmaceutical and biotechnology companies are the primary strategic drivers in this space. They control the intellectual property platforms, the clinical development infrastructure, and the commercial relationships needed to bring these modalities to patients. The strategic priorities most relevant to this group include:

• Platform Investment vs. Asset Acquisition: Companies must decide whether to build internal expertise in novel modalities — investing in conjugation chemistry, bispecific engineering, or PROTAC design — or to access them through licensing, partnerships, and acquisitions. Given the platform IP complexity of bispecifics and PROTACs in particular, many mid-sized biotechs view early platform access as more capital efficient than independent development.
• Indication Sequencing: With limited development resources, the choice of first indication for a novel modality is both a scientific and commercial decision. ADCs, for example, have expanded from early HER2-focused programs toward a broader range of validated tumor antigens, substantially expanding addressable patient populations.
• CMC as Competitive Advantage: For ADCs and bispecific antibodies especially, manufacturing process innovation — improved conjugation site selectivity, higher-yield bispecific expression systems — can meaningfully differentiate a product on both safety profile and commercial scalability.

For Contract Research and Manufacturing Organizations
Service providers — both CROs supporting development and CDMOs enabling manufacturing — are experiencing significant demand growth tied to these modalities, but differentiation is increasingly important:

• Specialized Capability Over Breadth: ADC programs require HPAPI-capable conjugation suites, specialized analytical development for DAR characterization, and in vivo payload efficacy/safety models. Organizations that have invested in these specific capabilities are in a materially stronger competitive position than generalist providers.
• Integrated Service Packages: Sponsors running complex bispecific or PROTAC programs increasingly prefer partners that can cover multiple stages — cell line development, process development, analytical method development, and GLP tox support — within a single relationship to minimize hand-off risk and data transfer complexity.
• Regulatory Science Expertise: For newer modalities like PROTACs and CPPs, the regulatory pathway is still being written. CROs that can offer regulatory strategy support alongside preclinical services — helping clients design studies that will satisfy novel IND requirements — provide distinctly higher value.

Shared Strategic Imperative: Translational Investment
Regardless of organization type, one consistent theme across all five modalities is the critical importance of translational science investment. These are not modalities where standard rodent models reliably predict human outcomes. Choosing appropriate preclinical models — including humanized platforms for immune-engaging bispecifics and related combination strategies — and designing studies that generate mechanistically meaningful data is one of the highest-leverage decisions an organization can make in early development.

Conclusion: From Concept to Clinical Reality

The five modalities explored in this article collectively represent the leading edge of a broader transformation in drug development philosophy — from blocking biology to co-opting it; from treating symptoms to eliminating root causes at the molecular level.

ADCs have already validated precision payload delivery as a clinically viable approach. Bispecific antibodies are reshaping the treatment paradigm in hematology and making meaningful inroads into solid tumors. PROTACs are rewriting the rules of target tractability through targeted protein degradation, opening the door to oncoproteins that have resisted drug development for decades. Engineered cytokines are attempting to solve the oldest problem in cancer immunotherapy — how to activate the immune system powerfully without destroying the patient. And cell-penetrating peptides, while the least mature of the group, hold perhaps the broadest long-term potential as delivery enablers for a generation of intracellular therapeutics yet to come.

The competitive advantage in this new landscape will not belong solely to those with the best science. It will belong to organizations — whether large pharma, emerging biotech, or specialized service providers — that can solve the manufacturing, analytical, and regulatory challenges with the same rigor they apply to biology. The future of drug development is protein-targeting. The question is who will be equipped to build it.

References

1. Collins, R. (2025). Cutting-Edge Protein Therapeutics: Reshaping the Future of Drug Development. LinkedIn Pulse.
2. Precedence Research. (2025). Protein Therapeutics Market Size, Share and Forecast 2025–2034. https://www.precedenceresearch.com/protein-therapeutics-market
3. IMARC Group. (2025). Protein Therapeutics Market Size, Growth Report 2026–2034. https://www.imarcgroup.com/protein-therapeutics-market
4. Grand View Research. (2025). Antibody Drug Conjugates Market Size, Share & Growth Report 2033. https://www.grandviewresearch.com/industry-analysis/antibody-drug-conjugates-market
5. SNS Insider. (2025). Antibody Drug Conjugates Market Size and Share Analysis to 2035. https://www.snsinsider.com/reports/antibody-drug-conjugates-market-4421
6. Astute Analytica. (2025). Antibody-Drug Conjugate Market Size and Forecast to 2035. https://www.astuteanalytica.com/industry-report/antibody-drug-conjugate-market
7. Roots Analysis. (2025). Bispecific Antibodies Market — Industry Trends and Global Forecasts to 2035. https://www.rootsanalysis.com/reports/bispecific-antibodies/286.html
8. Market Research Future. (2025). Bispecific Antibodies Market Size and Growth Forecast to 2035. https://www.marketresearchfuture.com/reports/bispecific-antibodies-market-21846
9. MarketsandMarkets. (2025). Targeted Protein Degradation Market — Global Forecast to 2035. https://www.marketsandmarkets.com/Market-Reports/targeted-protein-degradation-analysis-market-219352281.html
10. Evaluate Pharma. (2025). World Preview 2025: Outlook to 2030. Evaluate Ltd.
11. Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021). Unlocking the potential of antibody–drug conjugates for cancer therapy. Nature Reviews Clinical Oncology, 18(6), 327–344.
12. FDA. (2024). Hematology/Oncology (Cancer) Approvals & Safety Notifications. U.S. Food & Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
13. Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019). Bispecific antibodies: A mechanistic review of the pipeline. Nature Reviews Drug Discovery, 18(8), 585–608. https://doi.org/10.1038/s41573-019-0028-1
14. Békés, M., Langley, D. R., & Crews, C. M. (2022). PROTAC targeted protein degraders: The past is prologue. Nature Reviews Drug Discovery, 21(3), 181–200. https://doi.org/10.1038/s41573-021-00371-6
15. Waldmann, T. A. (2018). Cytokines in cancer immunotherapy. Cold Spring Harbor Perspectives in Biology, 10(12), a028472. https://doi.org/10.1101/cshperspect.a028472
16. Kristensen, M., Birch, D., & Mørck Nielsen, H. (2016). Applications and challenges for use of cell-penetrating peptides as delivery vectors for peptide and protein cargos. International Journal of Molecular Sciences, 17(2), 185. https://doi.org/10.3390/ijms17020185
17. Biotechnology Innovation Organization (BIO). (2024). Clinical Development Success Rates and Contributing Factors. https://go.bio.org/rs/490-EHZ-999/images/ClinicalDevelopmentSuccessRates2011_2020.pdf
18. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
19. Collins, R. (2026). Humanized Mouse Models: Enabling Translational Precision in Biologics Development. Scientia Potentia Est.